PET/CT Imaging Basics for Technologists: What You Need to Know
PET/CT has transformed oncologic imaging, nuclear cardiology, and neurologic assessment over the past two decades. For the technologist, it demands a synthesis of nuclear medicine principles, CT technique, radiopharmaceutical knowledge, and rigorous patient management. Whether you are cross-training into PET/CT, preparing for the NMTCB PET specialty examination, or simply looking to sharpen your protocol understanding, this guide provides a technically grounded foundation.
How PET/CT Works: The Fundamental Physics
Understanding PET imaging begins with the physics of positron emission and coincidence detection.
Positron Emission and Annihilation
PET radiopharmaceuticals are labeled with positron-emitting radionuclides. The most common is Fluorine-18 (F-18), which has a half-life of 109.8 minutes — long enough to allow dose preparation, transport, and imaging, but short enough to limit patient radiation dose.
When F-18 undergoes radioactive decay, it emits a positron (β+). That positron travels a short distance in tissue (typically 0.6–2.4 mm for F-18) before encountering an electron. The two particles undergo annihilation, producing two 511 keV gamma photons emitted in exactly opposite directions (180° apart).
The PET detector ring surrounds the patient and registers only coincident events — pairs of 511 keV photons detected simultaneously (within a timing window, typically 3–6 nanoseconds) by opposing detectors. This coincidence detection is what defines a PET event and allows localization of the radioactive source.
The Role of CT
The CT component of a PET/CT scanner serves two critical functions:
- Attenuation correction (AC): The CT scan generates a map of tissue densities used to correct the PET emission data for photon attenuation through the body. Without AC, deeper structures appear artifactually cold.
- Anatomic co-registration: The CT provides the structural anatomy onto which the metabolic PET data is fused, allowing precise anatomic localization of FDG-avid lesions.
Modern PET/CT scanners acquire both datasets sequentially within minutes, enabling near-simultaneous functional-anatomic imaging.
FDG: The Workhorse Radiopharmaceutical
18F-FDG (2-[18F]fluoro-2-deoxy-D-glucose) is the most widely used PET tracer and accounts for the vast majority of clinical PET/CT studies.
Mechanism of Uptake
FDG is a glucose analog. After IV injection, it follows the same initial metabolic pathway as glucose:
- FDG is transported into cells via glucose transporters (GLUT-1, GLUT-3)
- It is phosphorylated by hexokinase to FDG-6-phosphate
- Unlike glucose-6-phosphate, FDG-6-phosphate cannot proceed through glycolysis — it is metabolically trapped in the cell
This metabolic trapping means that tissues with high glucose metabolism — most cancers, inflamed tissue, and the brain — accumulate FDG in proportion to their metabolic activity. The result is high lesion-to-background contrast in metabolically active disease.
The SUV: Standardized Uptake Value
Quantitative assessment of FDG uptake is expressed as the Standardized Uptake Value (SUV):
SUV = (Activity concentration in tissue [MBq/mL]) / (Injected dose [MBq] / Body weight [g])
In practice, SUVmax (the maximum pixel value in a region of interest) is the most commonly reported metric. An SUVmax above 2.5 has historically been used as a threshold for malignancy, though this cutoff is heavily context-dependent and should never be applied in isolation.
Patient Preparation: The Technologist’s Critical Role
Patient preparation for FDG PET/CT is exacting. Non-compliance with prep instructions — particularly around blood glucose — is the most common source of non-diagnostic or degraded studies.
Why Blood Glucose Control Is Essential
Elevated blood glucose creates competition between FDG and endogenous glucose at the cellular transporter and hexokinase levels. High serum glucose suppresses FDG uptake in tumors while simultaneously increasing physiologic muscle and background uptake, degrading lesion-to-background contrast. Most institutions will not scan patients with blood glucose above 200 mg/dL.
Standard FDG PET/CT Patient Preparation
24 hours before the scan:
- Low-carbohydrate, high-protein diet (avoid bread, pasta, rice, potatoes, fruit, sugar, alcohol)
- No strenuous exercise — skeletal muscle FDG uptake from recent exercise creates significant artifacts
Day of the scan:
- NPO for minimum 4–6 hours (plain water is encouraged; keeps patient hydrated, reduces urinary background)
- No caffeine, gum, candy, breath mints, or flavored beverages (all contain sugars or stimulate salivary uptake)
- Continue most medications unless specifically instructed otherwise; insulin is typically held for 4–6 hours
- No IV contrast within 2 hours (affects attenuation correction values)
- Wear warm, comfortable clothing without metal — exam rooms are kept cool to minimize brown adipose tissue (BAT) activation
Blood glucose check at arrival:
- Confirm blood glucose with fingerstick glucometer before proceeding
- Target: ≤ 150–200 mg/dL (institutional thresholds vary; many prefer ≤ 150 mg/dL)
- Document glucose level in the procedure record
- If glucose is too high: notify the reading physician; the study may need to be rescheduled
Diabetic Patient Management
Insulin-dependent diabetic patients require individualized preparation. The timing of the scan relative to meals and insulin administration is critical and should be coordinated with the ordering physician. Some protocols prefer morning appointments for diabetic patients to take advantage of fasting overnight blood glucose levels.
Anxiety and Claustrophobia
PET/CT scanners have a larger, shorter bore than MRI — most patients tolerate the procedure without sedation. However, patients with significant anxiety should have a prescription anxiolytic available, with a driver escort required if sedation is administered.
Standard FDG PET/CT Acquisition Protocol
Radiopharmaceutical Administration
- FDG dose: Typically weight-based; common protocols use 0.14–0.19 mCi/kg (5.18–7.03 MBq/kg); total dose commonly 10–15 mCi (370–555 MBq) for oncologic imaging
- Administer via IV push, followed by saline flush
- Document administered activity, time of injection, lot number, and expiration
- Patient rests quietly in a warm room for 60 minutes post-injection (uptake phase)
During the uptake phase:
- Patient should remain still and quiet — avoid talking, walking, and muscle activity
- Room temperature should be maintained to suppress brown adipose tissue (BAT) uptake
- Warm blankets or warm room temperature reduce BAT activation, which manifests as uptake in the supraclavicular, neck, and paravertebral fat
- No phone use — jaw muscle activity from talking increases masseter and pharyngeal uptake
Voiding Before Imaging
- Patient voids immediately before scanning
- Reduces pelvic and bladder radiation dose
- Reduces urinary artifact that can obscure pelvic lesions
CT Acquisition
The CT is performed first and serves as the attenuation correction and anatomical reference scan. Protocols vary by indication:
| CT Protocol | Indications | Notes |
|---|---|---|
| Low-dose unenhanced CT | Standard oncologic staging | Minimizes overall study dose; sufficient for AC and co-registration |
| Diagnostic-quality CT with IV contrast | When CT is a primary diagnostic element | Requires separate contrast timing; higher dose |
| Head-to-thigh | Most oncologic indications | Standard field of view |
| Skull base to mid-thigh | Melanoma, lymphoma | Extended superior coverage |
| Whole-body (vertex to toes) | Melanoma, sarcoma | Extended inferior coverage |
Breathing instructions during CT: Shallow breathing or a brief end-expiration breath hold is preferred to avoid respiratory misregistration between CT and PET images. A misregistered dome of the liver can create spurious liver dome defects on the fused images.
PET Acquisition
- Acquisition mode: 3D mode standard on modern scanners (higher sensitivity than 2D)
- Time-of-flight (TOF): Now standard; improves signal-to-noise ratio, especially in larger patients
- Bed positions: Typically 6–8 bed positions for a skull base-to-thigh acquisition
- Time per bed position: 1.5–3 minutes per position (varies by scanner sensitivity and protocol)
- Total PET scan time: 15–30 minutes
- Image reconstruction: OSEM iterative reconstruction with TOF and PSF (point spread function) modeling; attenuation and scatter correction applied
Common Clinical Indications
FDG PET/CT is most established and most useful in oncology, with well-defined roles in several tumor types:
| Indication | Role of FDG PET/CT |
|---|---|
| Lymphoma (Hodgkin’s and aggressive NHL) | Staging, interim response, end-of-treatment assessment; gold standard |
| Lung cancer (NSCLC) | Staging, identifying nodal and distant metastases, post-treatment surveillance |
| Head and neck cancer | Staging, detecting cervical nodal metastases, identifying unknown primary |
| Colorectal cancer | Restaging with elevated CEA; identifying recurrence when CT/MRI equivocal |
| Melanoma | Staging, detecting distant metastases (Stage III/IV) |
| Esophageal cancer | Staging and restaging, monitoring response to neoadjuvant therapy |
| Thyroid cancer (poorly differentiated) | Radioiodine-negative, FDG-avid disease |
| Brain tumors | Differentiating tumor recurrence from radiation necrosis |
| Cardiac viability | Identifying hibernating myocardium for surgical revascularization decision |
| Neurology | Dementia differentiation; epilepsy focus localization |
Important limitation: FDG PET/CT has reduced sensitivity for mucinous tumors, well-differentiated hepatocellular carcinoma, prostate cancer, low-grade lymphomas, and small renal cell carcinomas — all characterized by relatively low FDG avidity. An understanding of tumor biology helps set appropriate expectations.
Radiation Safety in PET/CT
PET/CT involves radiation exposure from two sources: the injected FDG and the CT scan. The technologist’s radiation safety practices affect both themselves and their patient.
Patient Effective Dose
| Component | Approximate Dose |
|---|---|
| FDG (10 mCi / 370 MBq) | ~7 mSv |
| Low-dose CT (AC scan) | ~3–7 mSv |
| Diagnostic-quality CT | Up to 15–20 mSv |
| Total typical oncologic PET/CT | ~10–14 mSv |
For context, the average annual background radiation in the United States is approximately 3 mSv. A typical whole-body FDG PET/CT delivers roughly 3–5 times background annual dose — significant, but justified by the diagnostic information in appropriate clinical scenarios.
Dose Reduction Strategies
- Use weight-based FDG dosing protocols rather than fixed doses
- Optimize CT protocols — low-dose CT is adequate for attenuation correction; reserve diagnostic CT for indications that require it
- Encourage hydration and frequent voiding to reduce bladder dose from urinary FDG excretion
- Use 3D acquisition mode and TOF reconstruction to achieve diagnostic image quality at lower injected doses
- Avoid repeat scans unless clinically necessary
Technologist Occupational Exposure
NMTs working in PET/CT face higher occupational exposure than general radiology technologists because the patient becomes a radiation source for approximately 5–6 hours post-injection. Key practices:
- Distance: Radiation intensity falls with the inverse square of distance — doubling your distance from the patient reduces exposure by 75%
- Time: Minimize dwell time in close proximity to injected patients
- Shielding: Use syringe shields for FDG administration; some labs use PET-rated shielding glass in injection preparation areas
- Dosimetry: Wear whole-body and ring dosimeters; review dose records quarterly
- Pregnancy and lactation: Pregnant technologists should follow institutional ALARA policies, often involving temporary reassignment from PET work
Non-FDG PET Tracers: A Growing Landscape
F-18 FDG remains dominant, but the PET/CT landscape is expanding rapidly with alternative tracers that target specific biological processes:
| Tracer | Target | Key Indication |
|---|---|---|
| 68Ga-DOTATATE (NETSPOT) | Somatostatin receptors | Neuroendocrine tumors |
| 18F-NaF | Bone hydroxyapatite | Bone metastases |
| 18F-Florbetapir / Florbetaben | Amyloid plaques | Alzheimer’s disease diagnosis |
| 18F-PSMA-1007 / 68Ga-PSMA-11 | Prostate-specific membrane antigen | Prostate cancer staging and recurrence |
| 18F-Fluciclovine (AXUMIN) | Amino acid transporter | Prostate cancer recurrence |
As theranostic programs expand — pairing diagnostic tracers with therapeutic radiopharmaceuticals targeting the same receptor — nuclear medicine technologists will increasingly be involved in the preparation and administration of therapeutic agents. Understanding the foundational PET/CT principles covered here is the prerequisite for that expanded role.
Conclusion
PET/CT represents the convergence of nuclear medicine expertise and CT proficiency into one of the most diagnostically powerful tools in modern medicine. For the technologist, mastery means understanding FDG biology deeply enough to anticipate uptake patterns, preparing patients thoroughly enough to ensure diagnostic quality scans, operating the system with technical precision, and maintaining radiation safety discipline throughout.
The field is expanding. New tracers, theranostic applications, and AI-assisted reconstruction are transforming what PET/CT can do — and what technologists are expected to know. Invest in ongoing education through SNMMI, NMTCB, and ASNC resources to stay current.
Ready to earn CE credits in PET/CT and nuclear medicine? Explore our recommended CE platforms for nuclear medicine technologists and NMTCB-approved courses that count toward both your CNMT and PET specialty credential maintenance.